ATI-450

Phase 2Small molecule

ATI-450 is one of 161 small molecule programs targeting Cryopyrin-Associated Periodic Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

160

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cryopyrin-Associated Periodic SyndromeActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Psoriatic ArthritisActive, not recruiting

COVID-19Active, not recruiting

Hidradenitis SuppurativaActive, not recruiting

Cryopyrin-Associated Periodic SyndromePhase 2

Active, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

Psoriatic ArthritisPhase 2

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Hidradenitis SuppurativaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Spikevax

Moderna

Preclinical

21 2

ATI-450

AAclaris Therapeutics, Inc.

Phase 2

1 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Singulair

AstraZeneca

Preclinical

1 7

Stivarga

Bayer

Preclinical

1 8

Aimovig

Amgen

Preclinical

1 9

Aldactone

Pfizer

Preclinical

1 10

Nexavar

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hidradenitis Suppurativa1 trial

ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

Completed·AAclaris Therapeutics, Inc.·Phase 2·NCT05216224·95 enrolled

Cryopyrin-Associated Periodic Syndrome1 trial

Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)

Terminated·AAclaris Therapeutics, Inc.·Phase 2·NCT04524858·1 enrolled

Psoriatic Arthritis1 trial

Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

Terminated·AAclaris Therapeutics, Inc.·Phase 2·NCT05511519·47 enrolled

Rheumatoid Arthritis1 trial

ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)

Completed·AAclaris Therapeutics, Inc.·Phase 2·NCT05279417·251 enrolled

Methotrexate1 trial

Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA

Completed·AAclaris Therapeutics, Inc.·Phase 2·NCT04247815·25 enrolled

1 more indication

COVID-191 trial

A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)

Completed·UUniversity of Kansas Medical Center·Phase 2·NCT04481685·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for ATI-450. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ATI-450 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ATI-450. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aclaris Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAclaris Therapeutics, Inc.

ATI-450

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hidradenitis Suppurativa1 trial

Cryopyrin-Associated Periodic Syndrome1 trial

Psoriatic Arthritis1 trial

Rheumatoid Arthritis1 trial

Methotrexate1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News